|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 三联疗法根除十二指肠溃疡病患者Hp感染效果及影响因素分析显示文摘目的研究十二指肠溃疡患者使用三联疗法治疗幽门螺杆菌(Hp)感染的根除率,评估患者依从性、年龄、性别对于此类人群根除Hp治疗的影响。方法新发十二指肠溃疡并明确有Hp感染的1038例患者均接受三联(洛赛克或耐信联合克拉霉素与阿莫西林)7d疗法行根除Hp治疗,之后予以耐信或洛赛克治疗35d。系统治疗完成后6—8周复查胃镜。结果十二指肠溃疡病患者Hp根除率为77.0%。40岁以下人群的治疗依从性较差,40岁以下与40岁以上患者的Hp根除率有统计学差异(P〈0.05)。不同性别十二指肠溃疡患者的Hp根除率无统计学差异(P〉0.05)。结论三联7d疗法对十二指肠溃疡病患者Hp的根除率较低,患者对治疗的依从性、年龄是影响十二指肠溃疡患者Hp根除率的重要因素。 | 袁志芳 张川 张澍田 高峰 阎雪燕 高辉 段卓洋 | 2009 | 山东医药2009，49，16： | 34 |
| 2 | Furazolidone,amoxicillin,bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori显示文摘AIM:To compare the efficacy and side effect profiles of three furazolidone and amoxicillin-based quadruple rescue therapies for the eradication of Helicobacter pylori(H pylori).METHODS:Patients who failed in the H pylori eradication therapy for at least one course were randomly allocated into three groups.Group A received rebaprazole 10 mg + amoxicillin 1 g + furazolidone 100 mg,and bismuth subcitrate 220 mg,twice daily for 1 wk;group B received the same regimen of group A but for 2 wk;and group C received the same regimen of group B,but furazolidone was replaced by furazolidone 100 mg three times daily.To record the side effect profiles at the end of the treatment,H pylori eradication was assessed with 13C-urea breath test 4 wk after therapy.RESULTS:Sixty patients were enrolled including 28 males,and 20 patients in each group.The average age of the patients was 49.2 years,ranging from 18 to 84 years.H pylori eradication rates with per-protocol analysis were 82%,89% and 90% in the three groups,respectively.Side effects were found in 11 patients,including mild dizziness,nausea,diarrhea and increased bowel movement.None of the 11 patients needed treatment for their side effects.CONCLUSION:One-or two-week furazolidone and amoxicillin-based quadruple rescue therapy with a low dose furazolidone(100 mg bid) for the eradication of H pylori is effective.Extending the antibiotic course to 14 d could improve the eradication rates. | Hong Cheng Fu-Lian Hu | 2009 | World Journal of Gastroenterology2009，15，7： | 26 |
| 3 | 新视角——质子泵抑制剂及其体外抑制幽门螺杆菌作用研究进展显示文摘胃质子泵H+-K+ATP酶的发现,为抗胃酸分泌新药的研究提供了新的可能。从1988年第一个质子泵抑制剂奥美拉唑问世,经10多年来的临床应用,已成为一类疗效高、耐受性好、副作用少的抗酸药物和联合治疗幽门螺杆菌感染的药物。由于奥美拉唑的巨大成功,推动了其衍生物的研究开发,新的质子泵抑制剂药品陆续上市。本文对质子泵、质子泵抑制剂及其作用特点以及质子泵抑制剂对幽门螺杆菌的抑制机制研究进展进行简要综述。 | 赵飞 张建中 曾浔 | 2005 | 中国全科医学2005，8，11： | 24 |
| 4 | “Rescue” regimens after Helicobacter pylori treatment failure显示文摘Helicobacter pylori (H pylori) infection is the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. After more than 20 years of experience in H pylori treatment, in my opinion, the ideal regimen to treat this infection is still to be found. Currently, apart from having to know first-line eradication regimens well, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a 'rescue' treatment depends on which treatment is used initially. If a clarithromycin- based regimen was used initially, a subsequent metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacin- based combination would be a third 'rescue' option. Alternatively, it has recently been suggested that levofloxacin-based rescue therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, a quadruple regimen may be reserved as a third-line rescue option. Finally, rifabutin-based rescue therapy constitutes an encouraging empirical fourth- line strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H pylori eradication can finally be achieved in almost all patients if several rescue therapies are consecutively given. Therefore, the attitude in H pylori eradication therapy failure, evenafter two or more unsuccessful attempts, should be to fight and not to surrender. | Javier P Gisbert | 2008 | World Journal of Gastroenterology2008，14，35： | 20 |
| 5 | 质子泵抑制剂临床应用进展显示文摘质子泵抑制剂(proton pump inhibitor,PPI)是一类作用于H+-K+-ATP酶的强效抑酸药,临床药物包括奥美拉唑、兰索拉唑、泮托拉唑、雷贝拉唑和埃索拉唑。此类药物广泛用于治疗各种酸相关性疾病,如消化性溃疡、胃食管反流病、胃泌素瘤等的治疗, | 王蔚虹 王小蕾 | 2011 | 中国医院用药评价与分析2011，11，6： | 16 |
| 6 | 质子泵抑制剂和左氧氟沙星为基础的三联疗法作为一线方案根除幽门螺杆菌的荟萃分析显示文摘目的评价质子泵抑制剂(PPI)和左氧氟沙星为基础的三联疗法作为一线方案根除幽门螺杆菌的疗效与安全性。方法在Medline、Embase、OVID、Cochrane Library、Clinical evidence online、Socolar检索平台和CNKI中国期刊全文数据库(1994至2008年)中检索2008年5月17日之前已发表的关于PPI和左氧氟沙星为基础的三联疗法作为一线方案根除幽门螺杆菌的随机对照临床试验。应用Jadad评分对纳入的研究进行质量评价。利用Stata9.0软件进行数据分析,根据异质性检验结果,选择相应的效应模型进行荟萃分析。并通过Egger回归和剪切-添补的方法评定是否存在发表偏倚,利用剪切-添补的方法对未发表的研究结果进行估计。结果按入选标准,共纳入11个随机对照临床试验,共1926例幽门螺菌感染者纳入荟萃分析。荟萃分析表明:作为一线方案,PPI和左氧氟沙星为基础的三联疗法与标准三联疗法比较,其根除率高,比值比(OR)值为1.56[95%可信区间(cI)为1.25~1.94,P=0.000],不良反应发生低,OR值为0.57(95%CI为0.44~0.74,P=0.000),依从性差异无统计学意义,OR值为0.72(95%CI为0.34~1.49,P=0.374)。结论PPI和左氧氟沙星为基础的三联疗法可以有效地根除幽门螺杆菌,可以作为根除幽门螺杆菌的一线方案。 | 张智峰 赵钢 刘丽娜 | 2008 | 中华医学杂志2008，88，38： | 13 |
| 7 | H pylori eradication:A randomized prospective study of triple therapy with or without ecabet sodium显示文摘AIM: To investigate whether adding ecabet sodium to the standard triple therapy for H pylori infection improve eradication rate. METHODS: Two hundred and fifty-seven H pylori-infected patients were randomly assigned to standard triple therapy (group A, n = 129) or triple therapy plus ecabet sodium (group B, n = 128). Successful eradication was defined as a negative 13C-urea breath test 6-8 wk after completion of treatment. RESULTS: After completion of therapy, 194/257 patients showed negative 13C-urea breath test results. According to intention-to-treat analysis, the infection was eradicated in 93/129 (72.1%) patients in group A and 101/128 (78.9%) in group B (P = 0.204). Per-protocol analysis showed successful eradication in 93/118 (78.8%) patients from group A and 101/114 (88.6%) from group B (P = 0.044). There were no significant differences in the side effects experienced by the patients in the two treatment groups. CONCLUSION: Our results suggest that the addition of ecabet sodium improves the efficacy of the standard triple therapy for H pylori. | Hyung Wook Kim Gwang Ha Kim Jong Yun Cheong Ung Suk Yang Seung Keun Park Chul Soo Song Dae Hwan Kang Geun Am Song | 2008 | World Journal of Gastroenterology2008，14，6： | 9 |
| 8 | H^+-K^+-ATP酶的分布及其抑制剂PPI的作用显示文摘胃壁细胞内H^+-K^+-ATP酶(胃质子泵)是胃酸分泌的最终环节,其可与质子泵抑制剂(proton pump inhibitor,PPI)不可逆结合而失活,进而抑制胃酸分泌。第一个PPI奥美拉唑1987年于瑞典上市后,兰索拉唑、泮托拉唑、雷贝拉唑、埃索美拉唑、艾普拉唑相继应用于临床。 | 廖妍 白岚 | 2016 | 广东医学2016，37，9： | 8 |
| 9 | 治疗的依从性、年龄、性别对胃溃疡患者使用三联7天疗法根除幽门螺杆菌治疗的影响显示文摘目的研究胃溃疡患者使用三联7天疗法治疗幽门螺杆菌(Helicobacter pylori,H.pylori)感染的根除率,评估患者依从性、年龄、性别对于此类人群根除H.pylori治疗的影响。方法将经胃镜检查确诊为新发胃溃疡,并经活组织病理学检查明确有H.py-lori感染的1 075例患者纳入研究范围,所有入选患者均接受三联(洛赛克或耐信20 mg/次、2次/天,联合克拉霉素500 mg/次、2次/天,与阿莫西林1 000 mg/次、2次/天)7天疗法行根除H.pylori治疗,之后予以耐信或洛赛克20 mg/次、1次/天、治疗49天。所有入选患者系统治疗完成后6-8周复查胃镜。结果40-59岁与60岁以上人群的胃溃疡患者对治疗的依从性差异无显著性,而40岁以下人群对治疗的依从性较差(P〈0.05)。〈40岁、40-59岁和≥60岁胃溃疡患者的H.pylori根除率分别为61.0%、72.7%和81.9%。〈40岁与40-59岁和≥60岁患者的H.pylori根除率差异有统计学意义(P〈0.05)。不同性别胃溃疡患者的H.pylori根除率差异无显著性(P〉0.05)。结论使用三联7天疗法治疗胃溃疡患者的H.pylori感染,H.pylori的根除率较低,患者对治疗的依从性、年龄是影响胃溃疡患者H.pylori根除率的重要因素,而性别对此无影响。 | 张川 袁志芳 张澍田 高峰 阎雪燕 高辉 段卓洋 | 2009 | 胃肠病学和肝病学杂志2009，18，10： | 5 |
| 10 | 乳铁蛋白联合标准疗法治疗儿童幽门螺杆菌感染的疗效显示文摘目的观察乳铁蛋白联合幽门螺杆菌(H.pylori)标准三联疗法对儿童H.pylori感染根除率的影响及其不良反应。方法将2012年1月至2013年1月确诊且未接受过根除治疗的H.pylori感染患儿90例随机分为两组,对照组45例接受标准三联疗法治疗,观察组45例在接受标准三联疗法同时联合应用乳铁蛋白,记录治疗过程中的不良反应,以及疗程结束后4周的H.pylori根除率。结果观察组H.pylori根除率为(91.11%,41/45),高于对照组的根除率(73.33%,33/45);观察组不良反应率为(4.44%,2/45),低于对照组的不良反应率(20.00%,9/45),差异均有统计学意义(P均<0.05)。结论乳铁蛋白能提高H.pylori根除率,减少不良反应的发生。 | 王艳丽 李春力 庄探月 程艳波 | 2014 | 临床儿科杂志2014，32，4： | 5 |
| 11 | Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication:A meta-analysis显示文摘AIM:To evaluate whether adding azithromycin to firstline Helicobacter pylori(H pylori)eradication improved eradication and reduced side effects.METHODS:Eligible articles were identified by searches of electronic databases.We included all randomized trials that compared azithromycin-containing with standard triple-therapy regimens for first-line treatment of H pylori infection.Statistical analysis was performed with Review Manager 5.0.10.Sub-analyses were also performed.RESULTS:We identified 14 randomized trials(1431 patients).Pooled H pylori eradication rates were 72.01%(95%CI:58.09%-85.93%)and 69.78%(95% CI:66.47%-73.09%)for patients with or without azithromycin by intention-to-treat analysis,and the odds ratio(OR)was 1.17(95%CI:0.64-2.14).The occurrence of side effects differed significantly and was 15.81%(95%CI:12.50%-19.12%)and 25.20%(95%CI:21.44%-28.96%)for treatment with or without azithromycin,respectively,and the summary OR was 0.58(95%CI:0.41-0.82).Furthermore,the azithromycin-containing group had a lower occurrence of diarrhea,nausea and taste disturbance.CONCLUSION:Our review suggests that azithromycincontaining triple-therapy regimens could be equally effective in eradication of H pylori compared with standard first-line triple-therapy regimens. | Jie Dong Xiao-Feng Yu Jian Zou | 2009 | World Journal of Gastroenterology2009，15，48： | 5 |
| 12 | 乳铁蛋白联合标准疗法根除幽门螺杆菌的荟萃分析显示文摘目的:系统性评价乳铁蛋白联合标准疗法对Hpylori根除率的影响,及根除过程中的不良反应发生率.方法:从常用电子数据库检索标准三联或四联疗法联合与未联合乳铁蛋白根除Hpylori的随机临床试验,荟萃分析各项研究的根除率和不良反应发生率的合并OR值;进行亚组分析和敏感性分析;以漏斗图检测发表偏倚.结果:共9项随机临床试验(1343例)符合纳入标准.标准疗法联合与未联合乳铁蛋白按意向治疗(ITT)分析的Hpylori的根除率分别为86.57%(95%CI:83.99%-89.15%)和74.44%(95%CI:71.14%-77.74%),合并OR值为2.26(95%CI:1.70-3.00);总不良反应发生率分别为9.05%(95%CI:6.83%-11.27%)和16.28%(95%CI:13.43%-19.13%),合并OR值0.15(95%CI:0.04–0.54).结论:联合乳铁蛋白可有效提高标准疗法的Hpylori根除率,降低根除过程中的不良反应发生率. | 邹健 董洁 于晓峰 | 2009 | 世界华人消化杂志2009，17，9： | 4 |
| 13 | Azithromycin in one week quadruple therapy for H pylori eradication in Iran显示文摘瞄准:调查根除率,耐心的依从和 1-wk 的 toler 能力基于 Azithromycin 的四倍的治疗对 2-wk 常规治疗。方法: 129 个 H pylori积极的病人的一个总数被使随机化到任何一个 omeprazole 20 mg ,铋潜水艇柠檬酸盐 240 mg , azithromycin 250 mg ,和灭滴灵 500 mg ,为 1-wk ( B-OAzM )两次每日的所有或 omeprazole 20 mg ,铋潜水艇柠檬酸盐 240 mg , amoxicillin 1 g ,并且灭滴灵 500 mg 为 2-wk (B操作维护管理)两次每日的所有。H pylori 感染被组织学和快速的 urease 在入口定义,感染的痊愈被否定的脲呼吸测试决定。结果:B-OAzM 和 B 操作维护管理生产的 H pylori 根除率基于一个意愿分别地是 74.1% 和 70.4% 对待分析,并且 78.1% 对 75.7% 分别地基于每协议分析。,差的依从的发生更低不显著地那么,比为 B 操作维护管理(3.5% 对 4.3%) 在病人使随机化到 B-OAzM,但是难耐在二个组(35% 对 33.3%) 是类似的。结论:基于的四倍的政体完成的 1-wk azithromycin 比得上标准 2-wk 的 H pylori 根除率四倍的治疗,并且与可比较的耐心的依从和复杂并发症被联系。 | Shahrokh Mousavi Jafar Toussy Siamak Yaghmaie Mehrdad Zahmatkesh | 2006 | World Journal of Gastroenterology2006，12，28： | 3 |
| 14 | Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile显示文摘AIM:To compare the efficacy of 7-d versus 14-d triple therapy for the treatment of H pylori infection in Chile,with a prevalence of 73% in general population. METHODS:H pylori-infected patients diagnosed by rapid urease test,with non-ulcer dyspepsia or peptic ulcer disease were randomized to receive omeprazole 20 mg bid,amoxicillin 1 g bid,and clarithromycin 500 mg bid for 7 (OAC7) or 14 (OAC14) d. Primary outcome was eradication rate 6 wk after the treatment. Subgroup analysis was carried out considering the eradication rate among patients with or without peptic ulcer disease and eradication rate among smokers or non-smokers. RESULTS:One hundred and thirty-one patients were randomized to OAC7 (n = 69) or OAC14 (n = 62). The overall eradication rate (intention-to-treat) was 78.3% in OAC7 and 85.5% in OAC14 groups,without a significant difference (P =0.37). No significant difference in the eradication rate was found among the patients with peptic ulcer disease (n = 31) between the OAC7 group (85.7%) and OAC14 group (87.5%). However,smokers had an obviously lower eradication rate compared to non-smokers,particularly in the OAC7 group (57.1% in smokers vs 83.6% in non-smokers; P = 0.06). Adverse effects rate were similar between both groups. CONCLUSION:Short-term efficacy of triple therapy with OAC for 7 d is comparable to 14 d in this high-prevalence population. Longer follow-up,and studies focused to some subgroups of patients (smokers and non-ulcerpatients) are necessary to support widespread use of 7-d instead of 10-14-d triple therapy in a developing country like Chile. | Arnoldo Riquelme Alejandro Soza Cesar Pedreros Andrea Bustamante Felipe Valenzuela Francisco Otarola Eduardo Abbott Marco Arellano Brenda Medina Alejandro Pattillo Douglas Greig Marco Arrese Antonio Rollan | 2007 | World Journal of Gastroenterology2007，13，21： | 3 |
| 15 | IGF-2基因印迹状态与临床病理因素的关系显示文摘目的:探讨胃癌组织中,IGF-2(insulin-like growth factors2)基因的印迹状态及其与各临床病理因素间的关系。方法:应用PCR、RT-PCR及限制性内切酶(ApaⅠ)酶切等方法,检测33例胃癌组织中IGF-2基因的印迹状态,分析IGF-2基因印迹丧失(loss of imprinting,LOI)及其与胃癌各临床病理因素之间的关系。结果:胃癌组织中,IGF-2基因印迹的丧失率为48.5%(16/33),癌近旁黏膜的IGF-2基因印迹丧失率为21%(7/33),癌远旁黏膜的丧失率为12.1%(4/33)。同时,在有淋巴结转移的胃癌病例中IGF-2基因印迹丧失率(60.9%)明显高于无淋巴结转移者(20.0%);TNM分期Ⅲ、Ⅳ期的胃癌IGF-2基因印迹丧失率(60.0%)明显高于Ⅰ、Ⅱ期者(12.5%)(P均<0.05)。结论:IGF-2基因印迹丧失是贯穿于胃癌发生、发展全过程的表观遗传异常,其与胃癌的临床、病理分期及病人预后相关。 | 陈腾 左青松 赵荣华 奉典旭 陈超 蒋一鸣 韩峰 | 2010 | 外科理论与实践2010，15，3： | 2 |
| 16 | 胃癌相关幽门螺杆菌与宿主细胞作用机制的研究显示文摘目的:鉴定幽门螺杆菌(Hp)与宿主细胞人类胃上皮细胞(AGS)作用后差异蛋白的改变。方法:应用双向电泳分离菌株26695与AGS细胞相互作用前后的蛋白,应用Image Master 2Dv3.1软件对蛋白图谱进行比较,对目的蛋白进行基质辅助激光解析及电离飞行时间质谱分析,应用Mascot软件进行蛋白搜库。结果:共监测到5个差异蛋白斑点,经质谱分析鉴定为2种蛋白,分别是热休克蛋白60和烷基过氧化还原酶。结论:烷基过氧化还原酶可能进入AGS细胞或结合于AGS细胞膜上,有助于明确Hp与宿主细胞相互作用后的致病过程。 | 于文胜 孙作成 徐慧民 许加友 孙充兵 高红雷 李国军 | 2011 | 中华肿瘤防治杂志2011，18，23： | 2 |
| 17 | 幽门螺杆菌与人巨噬细胞株作用蛋白组学比较显示文摘目的寻找幽门螺杆菌(Hp)与宿主细胞(U937)作用后的差异蛋白。方法利用双向电泳技术分离Hp26695和TN2株与U937细胞相互作用前后的蛋白,应用ImageMaster 2Dv3.1软件对蛋白图谱进行比较,对目的蛋白进行基质辅助激光解析及电离飞行时间质谱分析,应用Mascot软件进行蛋白图谱搜库比对。结果 2株作用后的细胞株共检测到2个差异蛋白斑点,经质谱分析鉴定与Mascot搜库证实,其中的1种差异蛋白为Hp热休克蛋白60。结论热休克蛋白60可能进入细胞或结合于宿主细胞膜上,其相关机制尚待进一步阐明。 | 吴庆刚 张建中 严子禾 李伯清 | 2012 | 中国公共卫生2012，28，1： | 1 |
| 18 | 营养与表观遗传学基因组印记关系的研究进展显示文摘表观遗传修饰中印记基因的异常不仅影响胚胎发育,还可诱发出生后的发育异常。早期营养可能改变基因印记的调节,而饮食是影响健康的重要因素,且与肿瘤关系密切。本文概括表观遗传学基因组印记和其在肿瘤发生中的作用机制及研究情况,详述食物营养与表观遗传学基因组印记的关系及研究技术,并对其未来的研究方向进行预测。 | 腾丽娟 李克 | 2007 | 汕头大学医学院学报2007，20，4： | 1 |
| 19 | 幽门螺杆菌对胃黏膜上皮细胞作用后的差异蛋白鉴定显示文摘目的:鉴定幽门螺杆菌(Hp)与宿主细胞(AGS)作用后的差异蛋白。方法:应用双向电泳分离TN2株与AGS细胞相互作用前后的蛋白,应用ImageMaster 2Dv3.1软件对蛋白图谱进行比较,对目的蛋白进行基质辅助激光解析及电离飞行时间质谱分析,应用Mascot软件进行蛋白搜库。结果:共监测到2个差异蛋白斑点,经质谱分析鉴定为2种蛋白,分别是热休克蛋白60和烷基过氧化还原酶。结论:对热休克蛋白60深入研究表明,热休克蛋白60可能进入AGS细胞或结合于AGS细胞膜上,相关幽门螺杆菌感染宿主细胞后续致病过程尚待进一步研究。 | 严子禾 吴庆刚 张建中 李伯清 | 2011 | 中国卫生检验杂志2011，21，10： | 1 |
| 20 | 功能性肠病的促动力药物治疗显示文摘 | 孙菁 袁耀宗 | 2007 | 临床消化病杂志2007，19，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员